Hikma's 1st-half profits rise 19.9% to $30.1M
Amman, Jordan-headquartered Hikma Pharmaceutical says that its revenues for the six months to June 30 were $154.9 million, up 17.6% on the comparable period last year. The firm added that the sales increase had pushed its gross profits up 19.9% to $30.1 million, representing diluted earnings per share of $17.20.
Hikma went on to explain that, to June 30, it had received regulatory approval for 82 drugs, which it cited as an indication of its progress this year given that it only achieved a total of 98 approvals in full-year 2005.
The firm added that construction of both its new cephalosporin manufacturing plant in Portugal, as well as its R&D laboratories in Jordan, is nearing completion. The company's share price jumped 9.5% to L4.00 on the day of the news.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze